Breaking News, Collaborations & Alliances

Isis Earns $6 Million AZ Payment

Continues development of cancer drugs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals has earned a $6 million payment from AstraZeneca for the continuation of a research collaboration to discover and develop novel antisense therapeutics, which includes three cancer targets. Additionally, Isis and AZ are developing two antisense drugs, ISIS-ARRx and ISIS-STAT3Rx, discovered by Isis and licensed to AZ for the treatment of cancer.   The collaboration, originating December 2012, combines AZ’s experience and expertise in developing anti-cancer agents with Is...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters